Active, not recruitingPhase 3NCT05627557
A Study to Evaluate the Efficacy and Safety of Obinutuzumab Versus MMF in Participants With Childhood Onset Idiopathic Nephrotic Syndrome
Studying Idiopathic nephrotic syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Hoffmann-La Roche
- Principal Investigator
- Clinical TrialsHoffmann-La Roche
- Intervention
- Obinutuzumab(drug)
- Enrollment
- 85 target
- Eligibility
- 2-25 years · All sexes
- Timeline
- 2023 – 2026
Study locations (30)
- Lucile Packard Children's Hospital - Stanford, Palo Alto, California, United States
- Memorial Healthcare System, Hollywood, Florida, United States
- Nicklaus Children's Hospital, Miami, Florida, United States
- Nemours Children's Hospital, Orlando, Florida, United States
- University of South Florida, Tampa, Florida, United States
- Children's Healthcare of Atlanta Center for Advanced Pediatrics, Atlanta, Georgia, United States
- Hackensack University Medical Center, Hackensack, New Jersey, United States
- Levine Children's Hospital, Charlotte, North Carolina, United States
- University of Utah - Primary Children's Hospital - PPDS, Salt Lake City, Utah, United States
- University of Virginia Health System, Charlottesville, Virginia, United States
- UZ Gent, Ghent, Belgium
- Irmandade Da Santa Casa de Misericordia de Porto Alegre, Porto Alegre, Rio Grande do Sul, Brazil
- Fundacao Faculdade Regional de Medicina de Sao Jose Do Rio Preto Hospital de Base - PPDS, São José do Rio Preto, São Paulo, Brazil
- Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo, São Paulo, São Paulo, Brazil
- Peking University First Hospital, Beijing, China
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05627557 on ClinicalTrials.govOther trials for Idiopathic nephrotic syndrome
Additional recruiting or active studies for the same condition.